These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 37516196

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
    Michaeli DT, Michaeli T.
    J Clin Oncol; 2022 Dec 10; 40(35):4095-4106. PubMed ID: 35921606
    [Abstract] [Full Text] [Related]

  • 4. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T, Jürges H, Michaeli DT.
    BMJ; 2023 May 09; 381():e073242. PubMed ID: 37160306
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Michaeli JC, Michaeli T, Trapani D, Albers S, Dannehl D, Würstlein R, Michaeli DT.
    Breast Cancer; 2024 Nov 09; 31(6):1144-1155. PubMed ID: 39320645
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.
    Michaeli DT, Michaeli T, Albers S, Michaeli JC.
    Target Oncol; 2024 Sep 09; 19(5):797-809. PubMed ID: 39085451
    [Abstract] [Full Text] [Related]

  • 11. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC.
    Eur J Health Econ; 2024 Aug 09; 25(6):979-997. PubMed ID: 37962724
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K, Gentilini A, Haslam A, Prasad V.
    Lancet Oncol; 2024 Aug 09; 25(8):979-988. PubMed ID: 39004098
    [Abstract] [Full Text] [Related]

  • 14. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J, Lan T, Lu H, Pan J.
    PLoS Med; 2024 Jan 09; 21(1):e1004332. PubMed ID: 38166148
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG.
    JAMA Netw Open; 2020 Nov 02; 3(11):e2024406. PubMed ID: 33170262
    [Abstract] [Full Text] [Related]

  • 17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA.
    Clin Ther; 2013 Jun 02; 35(6):808-18. PubMed ID: 23726388
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.